|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Specificity of increased des-gamma-carboxyprothrombin in hepatocellular carcinoma after vitamin K1 injection.
|
2821104 |
1987 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Exons I and II and donor and acceptor site of intron I of the prothrombin gene in two HCC cell lines, PLC/PRF/5 and huH-2, were analyzed by polymerase chain reaction (PCR), and the product was sequenced directly.
|
1309675 |
1992 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
An important marker for hepatocellular carcinoma is the presence of des-gamma-carboxy (abnormal) prothrombin.
|
7520347 |
1994 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This causes the secretion of elevated levels of the immature or des-gamma-carboxylated form of prothrombin, which is used as a marker of HCC.
|
7657295 |
1995 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We evaluated the prognostic significance of anti-p53 antibody in 86 patients with hepatocellular carcinoma (HCC) in comparison with clinicopathological factors: age, sex, etiology, smoking and drinking habits, history of blood transfusion, presence of encephalopathy and ascites, Child classification, Pugh score, bilirubin, albumin, prothrombin time, indocyanine green retention time at 15 min (ICG), underlying liver disease, alpha-fetoprotein (AFP), tumor size, number of tumors, differentiation degree of HCC, presence of extrahepatic metastasis and therapy for HCC.
|
9365042 |
1997 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Use of sensitive des-gamma-carboxy prothrombin (PIVKA II) assay, and lectin affinity chromatography separating HCC specific subspecies of AFP molecules with a more practical biochemical technique will further improve diagnosis.
|
10728807 |
2000 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Des-gamma-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma.
|
12684661 |
2003 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The sensitivity/specificity of hTERT mRNA and alpha-fetoprotein (AFP) mRNA in HCC diagnosis were 88.2%/70.0% for hTERT and 71.6%/67.5% for AFP, respectively. hTERT mRNA proved to be superior to AFP mRNA, AFP, and des-gamma-carboxy prothrombin in HCC diagnosis.
|
15867214 |
2005 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
[Optimal cut-off value of PIVKA-II for diagnosis of hepatocellular carcinoma--using ROC curve].
|
16998292 |
2006 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
[PIVKA-II as a serological marker of hepatocellular carcinoma].
|
16998285 |
2006 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In univariate analysis, two baseline parameters were associated with the occurrence of HCC: age (P = 0.01) and prothrombin (P = 0.04).
|
18803353 |
2008 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Exon 2 deletion splice variant of gamma-glutamyl carboxylase causes des-gamma-carboxy prothrombin production in hepatocellular carcinoma cell lines.
|
19383345 |
2008 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Impairment of clathrin-mediated endocytosis via cytoskeletal change by epithelial to fibroblastoid conversion in HepG2 cells: a possible mechanism of des-gamma-carboxy prothrombin production in hepatocellular carcinoma.
|
19020747 |
2008 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
A study about mechanisms of des-gamma-carboxy prothrombin's production in hepatocellular carcinoma.
|
18927526 |
2008 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MTHFR C677TT, PAI1 4G-4G, V Leiden Q506, and prothrombin G20210A in hepatocellular carcinoma with and without portal vein thrombosis.
|
18618228 |
2009 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Male sex, alpha-fetoprotein (AFP) > or = 400 ng/mL, HBV DNA level > or = 4 log(10) copies/mL, prolonged prothrombin time, tumor size > or = 2 cm, microvascular invasion, absence of capsular formation, moderate/poor tumor differentiation, and absence of postoperative interferon-alpha (IFN-alpha) treatment were associated with increased cumulative risk of HCC recurrence.
|
20422305 |
2010 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Phenotype-dependent production of des-γ-carboxy prothrombin in hepatocellular carcinoma.
|
21744129 |
2011 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The abilities of quantitative analyses of 7 genes hypermethylation in serum DNA, α-fetoprotein (AFP) and prothrombin-induced vitamin K absence II (PIVKA-II), and various combinations to detect HCC were evaluated in a training cohort of 164 HCV-infected patients (108 HCCs; 56 non-HCCs).
|
20883676 |
2011 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In multivariate analysis, infection with a genotype 3 was independently associated with an increased risk of HCC occurrence [hazard ratio 3.54 (95% CI, 1.84-6.81), P = 0.0002], even after adjustment for prothrombin activity and alcohol abuse [3.58 (1.80-7.13); P = 0.003].
|
21914071 |
2011 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
des-γ-carboxyl prothrombin production is associated with tumor angiogenesis in HCC.
|
22554292 |
2012 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we review and summarize the results of studies on the roles played by the α -fetoprotein (AFP) and prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) responses in terms of the monitoring of outcomes and prediction of prognosis after various HCC treatments.
|
24455683 |
2013 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Protein induced by vitamin K absence or antagonist II (PIVKA-II), an abnormal form of prothrombin, has been used as an aid in the diagnosis of hepatocellular cancer (HCC) as a tumor marker.
|
26210849 |
2015 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
High EVI1 expression was significantly associated with larger tumor size and higher level of des-γ-carboxy prothrombin, a tumor marker for HCC.
|
25959919 |
2015 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
PHC patients with hypersplenism who displayed elevated levels of alanine transaminase (ALT), aspartate transaminase (AST), γ-glutamyltransferase (GGT), ALK, phosphatase, and prolonged prothrombin time (PT) had a significantly increased risk of HCC.
|
26753954 |
2016 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
HCV patients carrying GA genotype were more likely to develop hepatocellular carcinoma (OR=5.4, 95% CI=1.09-27.05; P=0.026).We concluded that the risk of HCC was increased 5-fold in subjects carrying GA genotype of prothrombin G20210A gene.
|
26768578 |
2016 |